Home

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of...

Daniel Carlson -
0
TW's Take: this PR sums up quite succinctly what makes INmune different from other companies targeting Alzheimer's Disease. Once the FDA approves the trial...
Read more

Pardon Me

Daniel Carlson -
2
One of the strangest Thanksgiving Day traditions in this country is the annual pardoning of the Turkeys. This tradition, started by John F. Kennedy...
Read more

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for...

Daniel Carlson -
0
TW's Take: more outstanding pre-clinical data. Lantern will take LP-184 into phase 1 trials in 2023, which should be very interesting for investors.  DALLAS --...
Read more

Pot Watching…

Daniel Carlson -
14
As a kid, I grew up in the Boston area. Which makes me a life-long Red Sox fan. Since 2003, this has been a...
Read more

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

Daniel Carlson -
10
TW's Take: removing the financing overhang is great news for investors. The company now has a runway to reach key milestones over the next...
Read more

Trading Blog, November 17, 2022

Daniel Carlson -
5
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and...

Daniel Carlson -
0
TW's Take: this is excellent data. Showing the long-term benefits is going to be key to marketing the product and getting potential partners excited....
Read more

Trading Blog, November 16, 2022

Daniel Carlson -
3
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of...

Daniel Carlson -
0
TW's Take: good progress but really need to get the FDA's approval to dramatically move the needle on enrollment. Frustrating but will come. BOCA RATON,...
Read more

Crashing Bitcoins and Other Thoughts

Daniel Carlson -
18
Wil the last one in the Crypto room please turn out the lights? The last time I wrote about Crypto was in August when I...
Read more

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio...

Daniel Carlson -
0
TW's Take: this trial continues to run ahead of expectations and increased awareness will position ANIX for a strong move into data in 2023. SAN...
Read more

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

Daniel Carlson -
0
TW's Take: enVVeno is executing flawlessly in this trial, setting the company up as a great risk/reward when you look out a little over...
Read more

Dinner Table Talk

Daniel Carlson -
12
As a kid did you eat your vegetables first or save them for last, hoping your parents wouldn't notice? I always ate them first...
Read more

ParkerVision Secures Patent License Agreement with Hisense

Daniel Carlson -
0
TW's Take: this bodes very well for the upcoming Intel trial, which takes place in three months. Establishing precedent of companies licensing their patents...
Read more

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of...

Daniel Carlson -
6
TW's Take: another early stage partnership that positions TFF well for next-gen vaccines but does little to overcome the concerns around the company's finances....
Read more

TFF Delays Data and Other Thoughts Heading Into Year-End 2022

Daniel Carlson -
2
Yesterday afternoon TFF Pharma ($TFFP) announced delays in data from both their VORI and TAC phase 2 studies. In previous guidance, given by the...
Read more

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical...

Daniel Carlson -
12
TW's Take: tough to understate just how disappointing these delays are to investors. Management's guidance on the timing of these programs has been flat-out...
Read more

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use...

Daniel Carlson -
5
TW's Take: positive results that are meaningful to the big picture here but will be ignored in light of the continual delays in this...
Read more

Sanford M. Litvack Joins ParkerVision Board of Directors

Daniel Carlson -
0
TW's Take: not sure why this senior litigator would join the board unless he felt that PRKR has a compelling case. Interesting development to...
Read more

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss...

Daniel Carlson -
0
TW's Take: the scientific community is getting increasingly excited about Anixa's CAR-T treatment as demonstrated by its upcoming presentations at important conferences. SAN JOSE, Calif., Oct....
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.